Seth Klarman: portfolio of Baupost Group
Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.
Source: 13F filing with the US Securities and Exchange Commission dated May 12, 2017. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary Amended on May 25, 2017 – the version known today is shown.
You are looking at Q1 2017. Go to the latest filing (Q3 2026)
- Total value of stock positions
- 8.4B USD
- Positions
- 41
- Share of the ten largest
- 69.2%
The ten largest positions Q1 2017
- Cheniere Energy Inc 12.2%unchanged
- Viasat Inc 10.0%unchanged
- Twenty First Centy Fox Inc 7.3%unchanged
- Colony Northstar Inc 7.3%new
- Synchrony Financial 7.2%▼ −14.5%
- Allergan PLC 6.9%▼ −29.1%
- Qorvo Inc 5.8%new
- Dell Technologies 4.3%▼ −15.0%
- Pbf Energy Inc 4.1%unchanged
- Theravance Biopharma Inc 4.0%unchanged
Show all positions of this quarter
Choose a quarter (54 filings)
- Q3 2026
- Q2 2026
- Q1 2026
- Q4 2025
- Q3 2025
- Q2 2025
- Q1 2025
- Q4 2024
- Q3 2024
- Q2 2024
- Q1 2024
- Q4 2023
- Q3 2023
- Q2 2023
- Q1 2023
- Q4 2022
- Q3 2022
- Q2 2022
- Q1 2022
- Q4 2021
- Q3 2021
- Q2 2021
- Q1 2021
- Q4 2020
- Q3 2020
- Q2 2020
- Q1 2020
- Q4 2019
- Q3 2019
- Q2 2019
- Q1 2019
- Q4 2018
- Q3 2018
- Q2 2018
- Q1 2018
- Q4 2017
- Q3 2017
- Q2 2017
- Q1 2017
- Q4 2016
- Q3 2016
- Q2 2016
- Q1 2016
- Q4 2015
- Q3 2015
- Q2 2015
- Q1 2015
- Q4 2014
- Q3 2014
- Q2 2014
- Q1 2014
- Q4 2013
- Q3 2013
- Q2 2013
All positions Q1 2017
| Symbol | Weight | Shares | Reported value | Change | Held since |
|---|---|---|---|---|---|
| Viasat Inc | 10.0% | 13,158,137 | 839.8M USD | unchanged | Q2 2013 or earlier 16 quarters |
| Novagold Res Inc | 0.5% | 9,500,000 | 46.3M USD | unchanged | Q2 2013 or earlier 16 quarters |
| American Intl Group Inc | 0.3% | 1,259,012 | 26.9M USD | −51.5% reduced | Q2 2013 or earlier 16 quarters |
| Pbf Energy Inc | 4.1% | 15,724,175 | 348.6M USD | unchanged | Q3 2013 15 quarters |
| Cheniere Energy Inc | 12.2% | 21,726,340 | 1.0B USD | unchanged | Q1 2014 13 quarters |
| Keryx Biopharmaceuticals Inc | 1.9% | 25,791,678 | 158.9M USD | unchanged | Q1 2014 13 quarters |
| Theravance Biopharma Inc | 4.0% | 9,273,991 | 341.5M USD | unchanged | Q2 2014 12 quarters |
| Antero Res Corp | 3.9% | 14,505,881 | 330.9M USD | unchanged | Q3 2014 11 quarters |
| Veritiv Corp | 1.9% | 3,044,385 | 157.7M USD | unchanged | Q3 2014 11 quarters |
| Forward Pharma A/S | 1.4% | 5,575,407 | 119.9M USD | +3.9% increased | Q4 2014 10 quarters |
| Atara Biotherapeutics Inc | 1.3% | 5,359,632 | 110.1M USD | unchanged | Q4 2014 10 quarters |
| Paratek Pharmaceuticals Inc | 0.5% | 2,044,498 | 39.4M USD | unchanged | Q4 2014 10 quarters |
| Twenty First Centy Fox Inc | 7.3% | 19,137,469 | 619.9M USD | unchanged | Q3 2015 7 quarters |
| Twenty First Centy Fox Inc | 2.7% | 7,278,100 | 231.3M USD | unchanged | Q3 2015 7 quarters |
| RUN Sunrun | 0.2% | 2,848,082 | 15.4M USD | unchanged | Q3 2015 7 quarters |
| Allergan PLC | 6.9% | 2,432,603 | 581.2M USD | −29.1% reduced | Q1 2016 5 quarters |
| Innoviva Inc | 1.9% | 11,573,663 | 160.1M USD | −22.5% reduced | Q1 2016 5 quarters |
| Credit Accep Corp Mich | 0.6% | 244,400 | 48.7M USD | unchanged | Q2 2016 4 quarters |
| Liberty Media Corp Delaware | 0.6% | 1,994,010 | 47.2M USD | −33.4% reduced | Q2 2016 4 quarters |
| SYF Synchrony Financial | 7.2% | 17,665,000 | 605.9M USD | −14.5% reduced | Q3 2016 3 quarters |
| DELL Dell Technologies | 4.3% | 5,652,459 | 362.2M USD | −15.0% reduced | Q3 2016 3 quarters |
| Conyers Pk Acquisition | 0.5% | 3,712,500 | 39.4M USD | unchanged | Q3 2016 3 quarters |
| Orexigen Therapeutics Inc | < 0.1% | 2,226,839 | 7.7M USD | unchanged | Q3 2016 3 quarters |
| Trilogy Metals Inc New | < 0.1% | 10,600,758 | 5.8M USD | unchanged | Q3 2016 3 quarters |
| Conyers Pk Acquisition | < 0.1% | 1,237,500 | 2.5M USD | unchanged | Q3 2016 3 quarters |
| MCK McKesson Corporation | 1.8% | 1,000,000 | 148.3M USD | unchanged | Q4 2016 2 quarters |
| CAH Cardinal Health | 1.0% | 1,030,000 | 84.0M USD | unchanged | Q4 2016 2 quarters |
| Liberty Interactive Corp | 0.8% | 1,481,719 | 65.9M USD | unchanged | Q4 2016 2 quarters |
| Chipmos Technologies Inc | 0.7% | 3,509,858 | 62.3M USD | unchanged | Q4 2016 2 quarters |
| Syngenta AG | 0.6% | 527,968 | 46.7M USD | −29.1% reduced | Q4 2016 2 quarters |
| Gty Technology Holdings Inc | 0.5% | 4,400,000 | 45.4M USD | unchanged | Q4 2016 2 quarters |
| COR Cencora | 0.5% | 502,474 | 44.5M USD | unchanged | Q4 2016 2 quarters |
| Centennial Resource Dev Inc | 0.5% | 2,407,153 | 41.7M USD | unchanged | Q4 2016 2 quarters |
| Cascadian Therapeutics Inc | 0.4% | 8,721,079 | 36.1M USD | +109.3% increased | Q4 2016 2 quarters |
| Saban Cap Acquisition Corp | 0.3% | 2,326,500 | 23.2M USD | unchanged | Q4 2016 2 quarters |
| Saban Cap Acquisition Corp | < 0.1% | 1,163,250 | 1.6M USD | unchanged | Q4 2016 2 quarters |
| Colony Northstar Inc | 7.3% | 47,905,461 | 618.5M USD | new | Q1 2017 1 quarter |
| Qorvo Inc | 5.8% | 7,185,514 | 492.6M USD | new | Q1 2017 1 quarter |
| QCOM Qualcomm | 3.5% | 5,216,000 | 299.1M USD | new | Q1 2017 1 quarter |
| Express Scripts Hldg Co | 1.0% | 1,228,619 | 81.0M USD | new | Q1 2017 1 quarter |
| Silver Run Acquisition | 0.8% | 6,615,554 | 69.0M USD | new | Q1 2017 1 quarter |
“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.
Plus 2 positions in convertible bonds and bonds worth 59.2M USD as reported – not included in the weights.
Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.
- Theravance Biopharma Inc principal 30.0M USD 37.8M USD
- Theravance Inc principal 22.5M USD 21.4M USD
Breakdown by sector
- Technology 7.8%
- Financials 7.2%
- Health Care 3.3%
- Industrials 0.2%
- not in our coverage 81.5%
Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.
How to read this page
- Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
- Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
- Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.
All superinvestor portfolios Screener: stocks held by superinvestors